Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants

Inclusion Criteria Concurrent Medication: Allowed: Administration of Pneumocystis carinii pneumonia prophylaxis according to CDC guidelines will be permitted. Patients must have: * For children \>= 3 months to 13 years of age: * HIV infection. For children \<3 months of age: * HIV infection or exposure. * Newborns must have birth weight \>= 2500 gm. * Absence at screen of any serious or unstable medical conditions. * Parent or guardian able to give written informed consent and willing to comply with study requirements. Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms or conditions are excluded: * Children with HIV associated malignancy requiring chemotherapy. * Children with clinical or laboratory assessments greater than Grade 1 in the Toxicity Table at the time of the screening. Concurrent Medication: Excluded: Chemotherapy. Prior Medication: Excluded: * Protease inhibitors. NOTE: * Patients who have taken investigational agents, immunomodulators, HIV-1 vaccines, glucocorticoids or unconventional therapies within one month prior to the day 0 of the study must be evaluated to determine the impact of these treatments on the study. Patients may be included or excluded on a case to case basis.